Aminoglycoside (neomycin) preference is for A-form nucleic acids, not just RNA: Results from a competition dialysis study
Aminoglycoside (neomycin) preference is for A-form nucleic acids, not just RNA: Results from a competition dialysis study
复制标题
DOI：
10.1021/ja035117c
复制
发表时间：
2003-08-27
影响因子：
15
通讯作者：
Willis, B
中科院分区：
文献类型：
--
作者：
Arya, DP;Xue, L;Willis, B
过去 50 年来，氨基糖苷类药物一直处于抗菌治疗的前沿。据信它们的特异性在于结合双链 RNA (rRNA)。对各种核酸形式与 9-氨基吖啶、奎纳克林和新霉素-吖啶缀合物进行了竞争透析研究。我们的结果表明，氨基糖苷类药物强烈倾向于与可采用 A 型构象的核酸结合。这些结果挑战了氨基糖苷类药物特异性仅针对双链体 RNA 的普遍看法。
Aminoglycosides have been at the forefront of antimicrobial therapy for the past 50 years. Their specificity is believed to lie in binding duplex RNAs (rRNA). Competition dialysis studies of various nucleic acid forms with 9-aminoacridine, quinacrine, and a neomycin-acridine conjugate were carried out. Our results suggest a strong preference for aminoglycoside binding to nucleic acids that can adopt an A-type conformation. These results challenge the common belief that aminoglycoside specificity is simply for duplex RNAs.